Generic Pharmaceuticals Pricing Antitrust Litigation
The causation theory is based on the premise that defendants' unlawful collusion to fix prices and allocate markets among generic drug manufacturers artificially inflated drug prices. This conduct eliminated competition, leading to supra-competitive prices that caused economic harm to consumers, health plans, and state entities. Expert economic reports support this by quantifying overcharges, demonstrating that prices would have been lower absent collusion, thus establishing a direct causal link between defendants' conduct and the damages suffered.
144
Pending actions
217
Total actions filed
Active
Status
08/05/2016
Established
Filing deadline
The primary deadlines are tied to the settlement process, with the objection deadline set for January 16, 2025. No overarching final deadline for all new claims outside settlement windows is explicitly stated, but procedural orders suggest ongoing case management and procedural deadlines, including a 14-day window following the resolution of defendants' dismissal motions as per Pretrial Order No. 79 ([source](https://www.paed.uscourts.gov/sites/paed/files/mdl-orders/16md2724_PTO79.pdf)).
Who qualifies
Plaintiffs must have purchased specific generic drugs listed in the settlement agreements or court orders during the relevant period, generally from May 1, 2009, to December 31, 2019. Eligible claimants include direct purchasers, end-payors such as consumers and health plans, and state entities that purchased these drugs within the jurisdiction and timeframe. Claimants are required to demonstrate purchase within the specified period and may need to provide proof of purchase.
Products involved
- Metformin
- Amlodipine
- Simvastatin
- Losartan
- Hydrochlorothiazide
- Gabapentin
- Omeprazole
- Sertraline
- Fluoxetine
- Atenolol
- Furosemide
- Pravastatin
- Carvedilol
- Tamsulosin
- Lisinopril
Alleged injuries
- Overpayment for generic drugs due to price-fixing scheme
Settlement landscape
Settlement amounts vary, with some cases settling for hundreds of thousands to over $10 million. The overall case valuation could reach hundreds of millions depending on the number of settled cases and damages awarded. The latest settlement notices and court orders indicate ongoing resolution efforts, with the most recent objection deadline set for January 16, 2025, and a scheduled fairness hearing for July 23, 2025.
Lead counsel
- Cuneo Gilbert Flannery & LaDuca, LLP
- Troutman Pepper
- Lowey Dannenberg, P.C.
This page is generated from the official JPML pending-MDL report and public court records, refreshed monthly. It is provided for attorney reference and is not legal advice.
